Yousif Capital Management LLC Decreases Stake in Intuitive Surgical, Inc. (NASDAQ:ISRG)

Yousif Capital Management LLC lowered its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 2.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 55,566 shares of the medical equipment provider’s stock after selling 1,364 shares during the quarter. Yousif Capital Management LLC’s holdings in Intuitive Surgical were worth $18,746,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently modified their holdings of the business. International Assets Investment Management LLC grew its holdings in Intuitive Surgical by 14.9% during the third quarter. International Assets Investment Management LLC now owns 2,116 shares of the medical equipment provider’s stock valued at $617,000 after purchasing an additional 275 shares during the period. Arkadios Wealth Advisors raised its position in Intuitive Surgical by 30.2% during the third quarter. Arkadios Wealth Advisors now owns 1,318 shares of the medical equipment provider’s stock valued at $385,000 after purchasing an additional 306 shares during the period. Global Retirement Partners LLC raised its position in Intuitive Surgical by 9.9% during the third quarter. Global Retirement Partners LLC now owns 1,852 shares of the medical equipment provider’s stock valued at $538,000 after purchasing an additional 167 shares during the period. Flagship Harbor Advisors LLC raised its position in Intuitive Surgical by 4.2% during the third quarter. Flagship Harbor Advisors LLC now owns 2,783 shares of the medical equipment provider’s stock valued at $813,000 after purchasing an additional 113 shares during the period. Finally, Fifth Third Wealth Advisors LLC raised its position in Intuitive Surgical by 74.0% during the third quarter. Fifth Third Wealth Advisors LLC now owns 1,018 shares of the medical equipment provider’s stock valued at $298,000 after purchasing an additional 433 shares during the period. Hedge funds and other institutional investors own 83.64% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the company. Barclays upped their price objective on Intuitive Surgical from $385.00 to $430.00 and gave the company an “overweight” rating in a research report on Thursday, January 25th. Royal Bank of Canada upped their target price on Intuitive Surgical from $400.00 to $432.00 and gave the company an “outperform” rating in a research note on Wednesday, January 24th. Raymond James upped their target price on Intuitive Surgical from $372.00 to $435.00 and gave the company an “outperform” rating in a research note on Thursday, January 25th. Piper Sandler upped their target price on Intuitive Surgical from $425.00 to $435.00 and gave the company an “overweight” rating in a research note on Friday. Finally, StockNews.com cut Intuitive Surgical from a “buy” rating to a “hold” rating in a research note on Thursday, February 29th. Five investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $396.17.

Intuitive Surgical Price Performance

NASDAQ ISRG traded up $8.15 during midday trading on Tuesday, hitting $377.08. 1,836,588 shares of the company traded hands, compared to its average volume of 1,677,112. The company has a market cap of $133.66 billion, a PE ratio of 68.07, a price-to-earnings-growth ratio of 5.69 and a beta of 1.36. The company’s 50-day simple moving average is $386.54 and its 200-day simple moving average is $344.98. Intuitive Surgical, Inc. has a 52 week low of $254.85 and a 52 week high of $403.76.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.40 by $0.10. The business had revenue of $1.89 billion for the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a return on equity of 12.91% and a net margin of 27.16%. The business’s revenue for the quarter was up 11.5% on a year-over-year basis. During the same quarter last year, the firm earned $1.00 EPS. On average, research analysts predict that Intuitive Surgical, Inc. will post 4.93 earnings per share for the current year.

Insider Activity

In other news, SVP Mark Brosius sold 196 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the sale, the senior vice president now owns 1,842 shares in the company, valued at approximately $736,800. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other news, SVP Mark Brosius sold 196 shares of the stock in a transaction on Tuesday, March 5th. The stock was sold at an average price of $400.00, for a total transaction of $78,400.00. Following the completion of the sale, the senior vice president now owns 1,842 shares in the company, valued at approximately $736,800. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, EVP Myriam Curet sold 4,318 shares of the stock in a transaction on Friday, January 26th. The shares were sold at an average price of $370.15, for a total value of $1,598,307.70. Following the sale, the executive vice president now owns 189 shares of the company’s stock, valued at approximately $69,958.35. The disclosure for this sale can be found here. In the last quarter, insiders sold 248,418 shares of company stock worth $95,927,097. Insiders own 0.80% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.